During a live webcast, CTO Clive Brown provided an update on the company's development plans and upcoming updates.
The group is continuing to validate the method for other epigenetic modifications and is looking to partner for commercial development.
Scientists from the University of Cambridge have developed a way for nanopores to read digital barcodes made up of protrusions on DNA strands.
The new R9 pore, which the company has licensed from VIB in Belgium and plans to release for the MinIon and the PromethIon, is based on the E. coli CsgG nanopore.
The researchers said the technique could be used to identify biomarkers specific to cancer or bacterial infection that are too small to detect by other methods.
Researchers are developing a nanopore sensing device that relies on restriction enzymes to target specific clinically relevant variants in pathogens.
The researchers’ method involves the use of third base pair labeling, PCR amplification, and nanopore sequencing.
According to local news reports, the company recently closed its facility in Providence, Rhode Island.
The company is developing a prototype system that it aims to later validate in clinical samples.
The survey, conducted by GenomeWeb in conjunction with investment bank William Blair, found that users operate their NGS instruments at different capacities.
In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.
Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.
According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.
National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.